Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JP-1366 (Zastaprazan) DDI Study with Clopidogrel, Aspirin, Atorvastatin, and Apixaban
NCT07265466Phase 1Recruiting
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Nov 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zastaprazan in gastroesophageal reflux disease (GERD) and gastric ulcer, sponsored by Onconic Therapeutics Inc. Primary endpoints: P2Y12 Reaction Unit at Day 8, Maximum arachidonic acid-induced platelet aggregation and 6 more. Started Nov 2025; status: recruiting.
02
Drugs
zastaprazan
03
Conditions
gastroesophageal reflux disease (GERD)gastric ulcer
Beyond the preview
Go deeper on NCT07265466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07265466.